Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled trial of inhaled SNG001 (interferon beta-1a) in hospitalised patients with moderate COVID-19
2020-004743-83Phase 3Unknown
- Sponsor
- Synairgen
- Start
- Oct 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing SNG001 (inhaled interferon beta-1a) with Placebo (2 arms). Primary endpoint: Primary endpoint: time to recovery. Status: unknown.
02
Drugs
interferon beta-1a
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-004743-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004743-83.